PT2762143E - Composições compreendendo 15-hepe e métodos de utilização das mesmas - Google Patents

Composições compreendendo 15-hepe e métodos de utilização das mesmas

Info

Publication number
PT2762143E
PT2762143E PT131765166T PT13176516T PT2762143E PT 2762143 E PT2762143 E PT 2762143E PT 131765166 T PT131765166 T PT 131765166T PT 13176516 T PT13176516 T PT 13176516T PT 2762143 E PT2762143 E PT 2762143E
Authority
PT
Portugal
Prior art keywords
hepe
compositions
methods
same
Prior art date
Application number
PT131765166T
Other languages
English (en)
Inventor
Rowe Jonathan
Duffy Kevin
Climax John
Original Assignee
Dignity Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dignity Sciences Ltd filed Critical Dignity Sciences Ltd
Publication of PT2762143E publication Critical patent/PT2762143E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
PT131765166T 2013-01-30 2013-07-15 Composições compreendendo 15-hepe e métodos de utilização das mesmas PT2762143E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same

Publications (1)

Publication Number Publication Date
PT2762143E true PT2762143E (pt) 2016-03-28

Family

ID=47891001

Family Applications (1)

Application Number Title Priority Date Filing Date
PT131765166T PT2762143E (pt) 2013-01-30 2013-07-15 Composições compreendendo 15-hepe e métodos de utilização das mesmas

Country Status (28)

Country Link
US (5) US20150224076A1 (pt)
EP (2) EP2762143B1 (pt)
JP (2) JP6363104B2 (pt)
KR (5) KR102274963B1 (pt)
CN (2) CN111214464A (pt)
AU (2) AU2014211628B2 (pt)
BR (1) BR112015018270A2 (pt)
CA (1) CA2897343C (pt)
CY (1) CY1117209T1 (pt)
DK (1) DK2762143T3 (pt)
ES (2) ES2759448T3 (pt)
GB (1) GB201301626D0 (pt)
HK (1) HK1200351A1 (pt)
HR (1) HRP20160203T1 (pt)
HU (1) HUE026901T2 (pt)
IL (3) IL239893A (pt)
MX (2) MX364646B (pt)
NZ (1) NZ709803A (pt)
PH (1) PH12015501582B1 (pt)
PL (1) PL2762143T3 (pt)
PT (1) PT2762143E (pt)
RS (1) RS54584B1 (pt)
RU (2) RU2671208C2 (pt)
SG (2) SG11201505457PA (pt)
SI (1) SI2762143T1 (pt)
SM (1) SMT201600069B (pt)
WO (1) WO2014118097A1 (pt)
ZA (2) ZA201505018B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3546446A1 (en) 2013-11-15 2019-10-02 DS Biopharma Limited Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids
SG11201605601UA (en) * 2014-01-10 2016-08-30 Mehar Manku Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
WO2016113635A1 (en) * 2015-01-16 2016-07-21 Dignity Sciences Limited Compositions comprising 15-hepe and methods of using the same
KR20240033300A (ko) 2015-04-28 2024-03-12 바스프 에이에스 비알코올성 지방간염의 예방 및/또는 치료를 위한 구조적으로 강화된 함황 지방산의 용도
CN107847477A (zh) * 2015-05-13 2018-03-27 Ds生物制药有限公司 包含15‑氧代‑epa或15‑氧代‑dgla的组合物及其制备和使用方法
EP3325094B1 (en) 2015-07-21 2021-01-06 Afimmune Limited Compositions comprising 15(s)-hepe for use in sensitizing cancer cells to radiation therapy
SG11201805149XA (en) * 2015-12-18 2018-07-30 Afimmune Ltd Compositions comprising 15-hepe and methods of using the same
WO2019111048A1 (en) 2017-12-06 2019-06-13 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
CA2149653C (en) 1993-10-01 1999-02-23 Frank S. S. Morton Methods and compositions for dispensing fragrances
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
ATE504557T1 (de) * 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
EP1390025B1 (en) 2001-05-30 2005-03-30 Laxdale Limited Use of coenzyme q (ubiquinone) and eicosapentaenoic acid (epa) for the treatment of non-hodgkin's lymphoma and psychiatric or neurological disorders
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
GB2409644B (en) 2003-12-31 2005-12-21 Igennus Ltd Formulation comprising eicosapentaenoic acid or an ester thereof and a triterpene or an ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060009522A1 (en) 2004-07-01 2006-01-12 Reza Dana Compositions and methods for treating eye disorders and conditions
EP1973536A2 (en) * 2006-01-05 2008-10-01 Reliant Pharmaceuticals, Inc. Treatment of fatty liver
EP2057473B1 (en) 2006-08-08 2014-11-12 Metabolon, Inc. Markers of non-alcoholic fatty liver disease (nafld) and non-alcoholic steatohepatitis (nash) and methods of use thereof
EP2143430B1 (en) * 2007-03-30 2015-09-23 Kowa Company, Ltd. Drug for preventing and/or treating fatty liver or nonalcoholic fatty liver disease
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
JP5523439B2 (ja) * 2009-02-20 2014-06-18 国立大学法人 東京大学 新規抗炎症性化合物
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
US9238634B2 (en) * 2010-08-19 2016-01-19 The University Of Tokyo Anti-inflammatory metabolite derived from omega-3-type fatty acid
WO2012031125A2 (en) 2010-09-01 2012-03-08 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
US10154977B2 (en) 2011-03-25 2018-12-18 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
JP2014530841A (ja) 2011-10-19 2014-11-20 ディグニティサイエンシスリミテッド Ｄｇｌａおよび／または１５−ｈｅｔｒｅを含む医薬組成物、ならびにその使用方法
CA2856715A1 (en) 2011-11-29 2013-06-06 Dignity Sciences Limited Compositions comprising 20-carbon fatty acids and methods of making and using same
PE20142459A1 (es) 2012-01-06 2015-01-23 Omthera Pharmaceuticals Inc Composiciones enriquecidas con dpa de acidos grasos omega 3 poliinsaturados en forma de acido libre
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
JP6370775B2 (ja) * 2012-05-10 2018-08-08 ソルテックス エヌエー エルエルシー 天然の特異的炎症収束性メディエータおよびその前駆物質を含有する、抗炎症活性を有する油
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
SG11201805149XA (en) 2015-12-18 2018-07-30 Afimmune Ltd Compositions comprising 15-hepe and methods of using the same

Also Published As

Publication number Publication date
AU2014211628B2 (en) 2018-04-19
WO2014118097A1 (en) 2014-08-07
US10813903B2 (en) 2020-10-27
ZA201605125B (en) 2018-06-27
AU2018206685A1 (en) 2018-08-02
MX2015009803A (es) 2015-10-29
ES2564025T3 (es) 2016-03-17
RS54584B1 (en) 2016-08-31
KR20210088733A (ko) 2021-07-14
PH12015501582A1 (en) 2015-10-05
EP3058943B1 (en) 2019-09-25
ZA201505018B (en) 2017-01-25
KR20240011872A (ko) 2024-01-26
US20210228524A1 (en) 2021-07-29
PH12015501582B1 (en) 2015-10-05
RU2018136872A (ru) 2018-11-27
CN105120872A (zh) 2015-12-02
KR20220119524A (ko) 2022-08-29
ES2759448T3 (es) 2020-05-11
KR102514913B1 (ko) 2023-03-27
HK1200351A1 (zh) 2015-08-07
MX2019005082A (es) 2019-08-12
RU2015136849A (ru) 2017-03-06
SMT201600069B (it) 2016-04-29
CY1117209T1 (el) 2017-04-05
PL2762143T3 (pl) 2016-06-30
IL239893A0 (en) 2015-08-31
CA2897343C (en) 2021-03-16
NZ709803A (en) 2020-05-29
SG10201806854XA (en) 2018-09-27
JP6363104B2 (ja) 2018-07-25
BR112015018270A2 (pt) 2017-07-18
SG11201505457PA (en) 2015-08-28
US20220347147A1 (en) 2022-11-03
US20200069626A1 (en) 2020-03-05
IL239893A (en) 2017-04-30
CN111214464A (zh) 2020-06-02
KR102274963B1 (ko) 2021-07-08
US20150224076A1 (en) 2015-08-13
SI2762143T1 (sl) 2016-04-29
GB201301626D0 (en) 2013-03-13
HUE026901T2 (en) 2016-07-28
MX364646B (es) 2019-05-03
RU2671208C2 (ru) 2018-10-30
JP2016511753A (ja) 2016-04-21
EP3058943A1 (en) 2016-08-24
JP2018172409A (ja) 2018-11-08
AU2014211628A1 (en) 2015-07-30
US20210244697A1 (en) 2021-08-12
HRP20160203T1 (hr) 2016-03-25
CA2897343A1 (en) 2014-08-07
IL265876A (en) 2019-06-30
DK2762143T3 (en) 2016-03-07
IL251639A0 (en) 2017-06-29
KR102434817B1 (ko) 2022-08-19
CN105120872B (zh) 2020-01-10
EP2762143A1 (en) 2014-08-06
KR20150112995A (ko) 2015-10-07
EP2762143B1 (en) 2015-12-02
KR20230047201A (ko) 2023-04-06

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
HK1218837A1 (zh) 組合物和方法
HK1218560A1 (zh) 組成與方法
HK1211866A1 (en) Antioxidant compositions and methods of using the same
IL265876A (en) Preparations that include 15-ohepa and methods of using them
HK1214171A1 (zh) 賽尼克韋羅組合物及其製備和使用方法
GB2527241B (en) Compositions and methods
EP2961382A4 (en) TOPICAL COMPOSITIONS AND METHODS OF USE
EP2964235A4 (en) ANTIMICROBIAL-ANTIBIOFILM COMPOSITIONS AND METHODS OF USE
GB201308072D0 (en) Compositions and methods
ZA201509262B (en) Tuberculosis compositions and methods of using the same
IL239840A0 (en) Polymyxins, preparations, methods of preparation and methods of use
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
GB201305813D0 (en) Compositions and methods
HK1220374A1 (zh) 用於治療碳氧血紅蛋白血症的組合物和方法
EP2964610A4 (en) VINYL SULFON-BASED 18F LABELING COMPOSITIONS AND METHOD AND USES THEREOF
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
GB201300628D0 (en) Compositions comprising 15-OHEPA and methods of using the same
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods
GB201308242D0 (en) Compositions and uses thereof